Long-term test-retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [11C]raclopride and high-resolution PET

Long-term test-retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [11C]raclopride and high-resolution PET
复制标题

DOI:
10.1038/jcbfm.2015.53
复制
发表时间:
2015-07-01
影响因子:
6.3
通讯作者:
Rinne, Juha O.
Rinne, Juha O.
中科院分区:
医学1区
文献类型:
--
作者:
Alakurtti, Kati;Johansson, Jarkko J.;Rinne, Juha O.

文献摘要

被引文献

相似文献

我们使用推注加输注方法和高分辨率正电子发射扫描仪测量了[C-11]雷氯必利在纹状体亚区、丘脑和皮质中结合的长期重测信度。7名健康男性志愿者接受了两次正电子发射断层扫描(PET)[C-11]雷氯必利评估,间隔5周进行复检。使用简化的参考组织模型将D-2/3受体可用性定量为结合潜力。纹状体的绝对变异性(VAR)和组内相关系数(ICC)值显示了非常好的再现性,尾状核、壳核和腹侧纹状体分别为4.5%/0.82、3.9%/0.83和3.9%/0.82。丘脑的可靠性也非常好,VAR为3.7%,ICC为0.92。皮质区的重测数据显示出良好至中等的重现性(6.1%至13.1%)。我们的结果与先前的[C-11]雷氯必利结合纹状体的重测研究一致。一个新的发现是[C-11]雷氯必利结合的变异性相对较低,提供了提示性证据,表明可以在体内用[C-11]雷氯必利PET研究纹状体外D-2/3结合,并在未来的研究中进行验证。
We measured the long-term test-retest reliability of [C-11]raclopride binding in striatal subregions, the thalamus and the cortex using the bolus-plus-infusion method and a high-resolution positron emission scanner. Seven healthy male volunteers underwent two positron emission tomography (PET) [C-11]raclopride assessments, with a 5-week retest interval. D-2/3 receptor availability was quantified as binding potential using the simplified reference tissue model. Absolute variability (VAR) and intraclass correlation coefficient (ICC) values indicated very good reproducibility for the striatum and were 4.5%/0.82, 3.9%/0.83, and 3.9%/0.82, for the caudate nucleus, putamen, and ventral striatum, respectively. Thalamic reliability was also very good, with VAR of 3.7% and ICC of 0.92. Test-retest data for cortical areas showed good to moderate reproducibility (6.1% to 13.1%). Our results are in line with previous test-retest studies of [C-11]raclopride binding in the striatum. A novel finding is the relatively low variability of [C-11]raclopride binding, providing suggestive evidence that extrastriatal D-2/3 binding can be studied in vivo with [C-11]raclopride PET to be verified in future studies.